Sagimet Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Sagimet Biosciences's estimated annual revenue is currently $1.5M per year.
- Sagimet Biosciences's estimated revenue per employee is $100,500
- Sagimet Biosciences's total funding is $293.7M.
Employee Data
- Sagimet Biosciences has 15 Employees.
- Sagimet Biosciences grew their employee count by 15% last year.
Sagimet Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO and Head Corporate Development | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Consultant | Reveal Email/Phone |
8 | Senior Accountant | Reveal Email/Phone |
9 | Clinical Operations Consultant | Reveal Email/Phone |
10 | President & CEO | Reveal Email/Phone |
Sagimet Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Sagimet Biosciences?
3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today
keywords:N/A
$293.7M
Total Funding
15
Number of Employees
$1.5M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sagimet Biosciences News
... mall unit in Hong Kong; liver disease and cancer biotech firm Sagimet Biosciences; and stroke treatment startup Bioxytran [BIXT].
Clinical-stage biopharmaceutical company Sagimet Biosciences Inc. has dropped plans for an initial public offering. The San Mateo, Calif.,...
If you were looking for another sign of the woeful conditions on Wall Street for biotechs, you can tee up the latest from Sagimet Biosciences. George Kemble.
SAN MATEO, Calif., March 16, 2021 /PRNewswire/ -- Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has g ...
Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing. The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise A ...
Other Companies in San Mateo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 15 | 0% | $7.5M |
#2 | $1.3M | 15 | N/A | N/A |
#3 | $0.5M | 15 | 0% | $74.7M |
#4 | N/A | 15 | 7% | N/A |
#5 | $1.3M | 15 | N/A | N/A |